Skip to main content

Articles By Sergio Schwartzman, MD

eye%20exa_1.jpg

My Take on New Ocular Screening Guidelines for Plaquenil

By Sergio Schwartzman, MD
14 October 2016

A recent article published by the American Academy of Ophthalmology presented new recommendations for screening of patients being managed with hydroxychloroquine that changed the previous monitoring paradigm. More importantly, it has repositioned hydroxychloroquine from one of the safest medications that rheumatologists use to a drug that can have potentially significant ocular morbidity (if used in doses greater than 5 mg per kilogram and or for prolonged periods of time).

Read Article
eye%20exam.jpg

My Take on New Ocular Screening Guidelines for Plaquenil

By Sergio Schwartzman, MD
12 October 2016

A recent article published by the American Academy of Ophthalmology presented new recommendations for screening of patients being managed with hydroxychloroquine that changed the previous monitoring paradigm. More importantly, it has repositioned hydroxychloroquine from one of the safest medications that rheumatologists use to a drug that can have potentially significant ocular morbidity (if used in doses greater than 5 mg per kilogram and or for prolonged periods of time).

Read Article
iritis-uveitis-e1333867439592_2.jpg

Adalimumab Approved for Uveitis

By Sergio Schwartzman, MD
01 July 2016

Autoimmune ophthalmic disease is a frequent challenge to rheumatologists from both a diagnostic and therapeutic perspective. Approved therapies are limited and have only been infrequently or comfortably utilized by rheumatologists and autoimmune ophthalmologists.

Read Article

Notes from the 2015 SPARTAN Meeting

By Sergio Schwartzman, MD
11 August 2015

Dr. Schwartzman reviews the proceedings of the 2015 Annual SPARTAN conference devoted to advances in spondyloarthritis.

Read Article
×